In first‐line treatment, trastuzumab, pertuzumab, and docetaxel in the CLEOPATRA study greatly extended the OS in patients with breast cancer that is HER2‐positive, with an ORR of 80.2%. The gene discussed is ERBB2; the disease is breast cancer.